Literature DB >> 8320054

Absorption and excretion of L-carnitine during single or multiple dosings in humans.

H Baker1, O Frank, B DeAngelis, E R Baker.   

Abstract

Changes of short-chain (free) and long-chain (acyl) carnitine activity (CA) in plasma, whole blood, red blood cells (rbc) and urine were induced (a) by ingestion of L-carnitine as a single dose of 500 mg, or 2500 mg, or (b) by ingestion of a daily dose of 2500 mg for 10 days. A single 500-mg dose induced insignificant increases of CA in blood constituents. However elevated free CA was noted in urine. Single or daily high doses--e.g. 2500 mg of carnitine--significantly increased free and acyl-CA in plasma, whole blood and urine, but these increases were low. Variations in dosage or frequency of carnitine intake led to no changes in rbc CA; presumably CA in plasma diffused only slowly into rbc. The apparent low absorption of carnitine suggests that oral therapy may not effect rapid repletion of body stores of CA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320054

Source DB:  PubMed          Journal:  Int J Vitam Nutr Res        ISSN: 0300-9831            Impact factor:   1.784


  6 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

Review 2.  Nutrition for improved sports performance. Current issues on ergogenic aids.

Authors:  P M Clarkson
Journal:  Sports Med       Date:  1996-06       Impact factor: 11.136

3.  Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet.

Authors:  Judit Bene; Katalin Komlósi; Beáta Gasztonyi; Márk Juhász; Zsolt Tulassay; Béla Melegh
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

4.  Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.

Authors:  S Pace; A Longo; S Toon; P Rolan; A M Evans
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 5.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.

Authors:  F Graziano; R Bisonni; V Catalano; R Silva; S Rovidati; E Mencarini; B Ferraro; F Canestrari; A M Baldelli; A De Gaetano; P Giordani; E Testa; V Lai
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.